Adaptive Biotechnologies Q2 2026 Earnings Call Transcript

Adaptive Biotechnologies held its Q2 2026 earnings conference call on July 29, 2026. The call was led by CEO Chad Robins, CFO Kyle Piskel, and other executives. They discussed the company's financial results for the second quarter, which were released earlier that day. The presentation included forward-looking statements and non-GAAP financial measures. Analysts from Piper Sandler, Guggenheim, BTIG, TD Cowen, JPMorgan, and Morgan Stanley participated in the Q&A session. The call covered the company's performance, strategic outlook, and market position in the biotechnology sector, particularly in minimal residual disease (MRD) testing.

First published Aug 4, 02:54 PM UTCUpdated Jul 30, 04:13 AM UTC1 reports · 1 sources

Editorial responsibility

Prepared by: WorldAttention Editorial Systems
Human review: No named human review is recorded for this page.
Automated steps: Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
Page status: Current automated evidence projection
Last updated: Jul 30, 04:13 AM UTCEditorial record as of Aug 4, 02:54 PM UTC

How automation and AI are used · Report a correction or rights issue

Wire timeline

currentJul 30, 04:13 AM UTC

Adaptive Biotechnologies Q2 2026 Earnings Call Transcript

Coverage sources

External reporting used to assemble this Story.

Adaptive Biotechnologies Q2 2026 Earnings Call TranscriptAll Articles on Seeking AlphaNeutral / independentJul 30, 04:13 AM UTC

Follow the context

Morgan Stanley